TD Cowen Starts Soleno Therapeutics Inc. (SLNO) at Buy

TD Cowen analyst Tyler Van Buren initiates coverage on Soleno Therapeutics Inc. (NASDAQ: SLNO) with a Buy rating and a price target of $110.00.

The analyst comments "Vykat XR bucked the trend of clinical shortcomings in PWS by becoming the first-approved treatment for hyperphagia in this devastating genetic syndrome. Management appears prepared to execute on a strong launch with a high price tag and sizable population to itself, and we are optimistic the PWS community's urgency will fuel significant uptake. We are initiating at Buy with a $110 DCF-based PT."

For an analyst ratings summary and ratings history on Soleno Therapeutics Inc. click here. For more ratings news on Soleno Therapeutics Inc. click here.

Shares of Soleno Therapeutics Inc. closed at $79.98 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Freedom Broker Upgrades Lifeway Foods (LWAY) to Buy
• Cantor Fitzgerald Reiterates Overweight Rating on Applied Materials (AMAT)